Methods for producing hepatocytes
11713448 · 2023-08-01
Assignee
Inventors
- Louise Kristina Hagbard (Sollentuna, SE)
- Carl Gunnar Jesper Ericsson (Hagersten, SE)
- Katherine Rachel Cameron (Edinburgh, GB)
- David Colin Hay (Midlothian, GB)
- Stuart John Forbes (East Lothian, GB)
- Hassan Rashidi (Edinburgh, GB)
Cpc classification
C12N2533/90
CHEMISTRY; METALLURGY
C12N5/0671
CHEMISTRY; METALLURGY
C12N5/0695
CHEMISTRY; METALLURGY
C12N2501/999
CHEMISTRY; METALLURGY
C12N2501/16
CHEMISTRY; METALLURGY
C12N5/0696
CHEMISTRY; METALLURGY
C12N2501/115
CHEMISTRY; METALLURGY
C12N2533/40
CHEMISTRY; METALLURGY
International classification
C12N5/00
CHEMISTRY; METALLURGY
Abstract
Methods for producing hepatocytes from pluripotent human stem cells are disclosed herein. The stem cells are plated on a cell culture substrate comprising two laminins. The stem cells are then exposed to different cell culture mediums to induce differentiation. The resulting hepatocytes have higher metabolic capacity compared to hepatocytes cultured on different substrates.
Claims
1. A method for producing hepatocytes, comprising: plating pluripotent human stem cells on a cell culture substrate comprising (i) a first laminin which is laminin-521 and (ii) a second laminin selected from the group consisting of laminin-111 and laminin-221, wherein the laminin-521 and the second laminin are each an intact protein; and culturing the pluripotent human stem cells on the cell culture substrate to obtain the hepatocytes, wherein the culturing is performed by: culturing the cells in an endoderm differentiation medium containing activin A, Wnt3a, and hepatocyte growth factor; culturing the cells in a hepatic specification medium containing a serum replacement and dimethyl sulfoxide; culturing the cells in a hepatic differentiation medium; and culturing the cells in a hepatic maturation medium containing hepatocyte growth factor (HGF).
2. The method of claim 1, wherein the weight ratio of the laminin-521 to the second laminin is from about 1:4 to about 1:1.
3. The method of claim 1, wherein the cells are cultured in the endoderm differentiation medium for a period of about 60 hours to about 84 hours.
4. The method of claim 1, wherein the cells are cultured in the hepatic specification medium for a period of about 84 hours to about 108 hours.
5. The method of claim 1, wherein the cells are cultured in the hepatic differentiation medium for a period of about 108 hours to about 132 hours.
6. The method of claim 1, wherein the cells are cultured in the hepatocyte maturation medium for a period of about 84 hours to about 108 hours.
7. The method of claim 1, wherein the activin A is present in the endoderm differentiation medium in an amount of about 50 ng/mL to about 150 ng/mL.
8. The method of claim 1, wherein the Wnt3a is present in the endoderm differentiation medium in an amount of about 20 ng/mL to about 100 ng/mL.
9. The method of claim 1, wherein the endoderm differentiation medium further includes RPMI 1640.
10. The method of claim 1, wherein the hepatic specification medium comprises 20% of the Serum Replacement, 1% non-essential amino acids, 0.33 mM beta-mercaptoethanol, and 1% of the dimethyl sulfoxide.
11. The method of claim 1, wherein the hepatocyte growth factor is present in the hepatic maturation medium in an amount of about 5 ng/mL to about 20 ng/mL.
12. The method of claim 1, wherein oncostatin m is present in the hepatic differentiation medium in an amount of about 10 ng/mL to about 30 ng/mL.
13. The method of claim 1, wherein the resulting hepatocytes exhibit CYP1A2 activity of at least 600,000 RLU/mg/mL or CYP3A activity of at least 800,000 RLU/mg/mL.
14. The method of claim 1, wherein the second laminin is laminin-221.
15. The method of claim 1, wherein the cell culture substrate further comprises a cadherin.
16. The method of claim 15, wherein the weight ratio of (the first laminin+the second laminin) to the cadherin is from about 5:1 to about 15:1.
17. The method of claim 1, wherein the cell culture substrate does not contain any differentiation inhibitors, feeder cells, differentiation inductors, or apoptosis inhibitors.
18. The method of claim 1, wherein the pluripotent human stem cells have a three-dimensional structure prior to culturing.
19. A method for producing hepatocytes, comprising: plating pluripotent human stem cells on a cell culture substrate comprising (i) a first laminin which is laminin-521 and (ii) a second laminin selected from the group consisting of laminin-111 and laminin-221, wherein the laminin-521 and the second laminin are each an intact protein; and culturing the pluripotent human stem cells on the cell culture substrate to obtain the hepatocytes, wherein the culturing is performed by: culturing the cells in an endoderm differentiation medium comprising activin A, Wnt3a, and hepatocyte growth factor; culturing the cells in a hepatic specification medium containing a serum replacement and dimethyl sulfoxide; culturing the cells in a hepatic differentiation medium containing insulin, dexamethasone, oncostatin M, and basic fibroblast growth factor; and culturing the cells in a hepatic maturation medium containing insulin, lithocholic acid, vitamin K, hepatocyte growth factor, and dexamethasone.
20. The method according to claim 19, wherein the resulting hepatocytes exhibit CYP1A2 activity of at least 600,000 RLU/mg/mL or CYP3A activity of at least 800,000 RLU/mg/mL.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1) The following is a brief description of the drawings, which are presented for the purposes of illustrating the exemplary embodiments disclosed herein and not for the purposes of limiting the same.
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(27)
(28)
(29)
(30)
(31)
(32)
(33)
(34)
(35)
DETAILED DESCRIPTION
(36) A more complete understanding of the compositions and methods disclosed herein can be obtained by reference to the accompanying drawings. These figures are merely schematic representations based on convenience and the ease of demonstrating the present disclosure, and are, therefore, not intended to define or limit the scope of the exemplary embodiments.
(37) Although specific terms are used in the following description for the sake of clarity, these terms are intended to refer only to the particular structure of the embodiments selected for illustration in the drawings, and are not intended to define or limit the scope of the disclosure. In the drawings and the following description below, it is to be understood that like numeric designations refer to components of like function.
(38) All publications, patents, and patent applications discussed herein are hereby incorporated by reference in their entirety.
(39) The singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.
(40) As used in the specification and in the claims, the term “comprising” may include the embodiments “consisting of” and “consisting essentially of.” The terms “comprise(s),” “include(s),” “having,” “has,” “can,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that require the presence of the named ingredients/steps and permit the presence of other ingredients/steps. However, such description should be construed as also describing compositions or processes as “consisting of” and “consisting essentially of” the enumerated ingredients/steps, which allows the presence of only the named ingredients/steps, along with any impurities that might result therefrom, and excludes other ingredients/steps.
(41) Numerical values in the specification and claims of this application should be understood to include numerical values which are the same when reduced to the same number of significant figures and numerical values which differ from the stated value by less than the experimental error of conventional measurement technique of the type described in the present application to determine the value.
(42) All ranges disclosed herein are inclusive of the recited endpoint and independently combinable (for example, the range of “from 2 to 10” is inclusive of the endpoints, 2 and 10, and all the intermediate values).
(43) The term “about” can be used to include any numerical value that can vary without changing the basic function of that value. When used with a range, “about” also discloses the range defined by the absolute values of the two endpoints, e.g. “about 2 to about 4” also discloses the range “from 2 to 4.” The term “about” may refer to plus or minus 10% of the indicated number.
(44) Several well-known references that may be relevant to the present disclosure include: Molecular Cloning: A Laboratory Manual (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), Gene Expression Technology (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991. Academic Press, San Diego, Calif.), “Guide to Protein Purification” in Methods in Enzymology (M. P. Deutshcer, ed., (1990) Academic Press, Inc.); PCR Protocols: A Guide to Methods and Applications (Innis, et al. 1990. Academic Press, San Diego, Calif.), Culture of Animal Cells: A Manual of Basic Technique, Second Ed. (R. I. Freshney. 1987. Liss, Inc. New York, N.Y.), Gene Transfer and Expression Protocols, pp. 109-128, ed. E. J. Murray, The Humana Press Inc., Clifton, N.J.), or the Ambion 1998 Catalog (Ambion, Austin, Tex.).
(45) As used herein, the term “laminin-521” refers to the protein formed by joining α5, β2 and γ1 chains together. The term should be construed as encompassing both recombinant laminin-521 and heterotrimeric laminin-521 from naturally occurring sources.
(46) As used herein, the term “laminin-111” refers to the protein formed by joining α1, β1 and γ1 chains together. The term should be construed as encompassing both recombinant laminin-111 and heterotrimeric laminin-111 from naturally occurring sources.
(47) As used herein, the term “laminin-221” refers to the protein formed by joining α2, β2 and γ1 chains together. The term should be construed as encompassing both recombinant laminin-221 and heterotrimeric laminin-221 from naturally occurring sources.
(48) The term “intact” refers to the protein being composed of all of the domains of the α-chain, β-chain, and γ-chain, with the three chains being joined together to form the heterotrimeric structure. The protein is not broken down into separate chains, fragments, or functional domains. The term “chain” refers to the entirety of the alpha, beta, or gamma chain of the laminin protein. The term “fragment” refers to any protein fragment which contains one, two, or three functional domains that possesses binding activity to another molecule or receptor. However, a chain should not be considered a fragment because each chain possesses more than three such domains. Similarly, an intact laminin protein should not be considered a fragment. Examples of functional domains include Domains I, II, III, IV, V, VI, and the G domain.
(49) Laminins are a family of heterotrimeric glycoproteins that reside primarily in the basal lamina. They function via binding interactions with neighboring cell receptors on the one side, and by binding to other laminin molecules or other matrix proteins such as collagens, nidogens or proteoglycans. The laminin molecules are also important signaling molecules that can strongly influence cellular behavior and function. Laminins are important in both maintaining cell/tissue phenotype, as well as in promoting cell growth and differentiation in tissue repair and development.
(50) Laminins are large, multi-domain proteins, with a common structural organization. The laminin molecule integrates various matrix and cell interactive functions into one molecule. A laminin protein molecule comprises one α-chain subunit, one β-chain subunit, and one γ-chain subunit, all joined together in a trimer through a coiled-coil domain. The twelve known laminin subunit chains can form at least 15 trimeric laminin types in native tissues. Within the trimeric laminin structures are identifiable domains that possess binding activity towards other laminin and basal lamina molecules, and membrane-bound receptors. For example, domains VI, IVb, and IVa form globular structures, and domains V, IIIb, and IIIa (which contain cysteine-rich EGF-like elements) form rod-like structures. Domains I and II of the three chains participate in the formation of a triple-stranded coiled-coil structure (the long arm).
(51) There exist five different alpha chains, three beta chains and three gamma chains that in human tissues have been found in at least fifteen different combinations. These molecules are termed laminin-1 to laminin-15 based on their historical discovery, but an alternative nomenclature describes the isoforms based on their chain composition, e.g. laminin-111 (laminin-1) that contains alpha-1, beta-1 and gamma-1 chains. Four structurally defined family groups of laminins have been identified. The first group of five identified laminin molecules all share the β1 and γ1 chains, and vary by their α-chain composition (α1 to α5 chain). The second group of five identified laminin molecules, including laminin-521, all share the β2 and γ1 chain, and again vary by their α-chain composition. The third group of identified laminin molecules has one identified member, laminin-332, with a chain composition of α3β3γ2. The fourth group of identified laminin molecules has one identified member, laminin-213, with the newly identified γ3 chain (α2β1γ3).
(52) The present disclosure relates to more efficient methods of culturing stem cells to obtain differentiated hepatocytes that behave more like primary hepatocytes. In particular, the stem cells are cultured on a substrate that contains laminin-521 and a second laminin selected from laminin-111 and laminin-221. This results in more differentiated hepatocytes with more natural behavior than cells grown on substrates containing an undefined and alternative blend of extracellular matrices.
(53) Differentiated cells typically require two things to survive and reproduce: (1) a substrate or coating that provides a structural support for the cell; and (2) a cell culture medium to provide nutrition to the cell. The substrate or coating (1) is typically formed as a layer in a container, for example a petri dish or in the well of a multi-well plate. Application of different cell culture mediums at appropriate time intervals in combination with the substrates containing two laminins result in mature hepatocytes with more natural functions/properties.
(54) The stem cells that can be used with the methods and materials disclosed herein are pluripotent human stem cells. Such stem cells can include induced pluripotent stem cells, embryonic stem cells, adult stem cells, fetal stem cells, amniotic stem cells, and generally any pluripotent stem cell.
(55) Initially, the stem cells are plated on a cell culture substrate. The substrate contains two laminins. The first laminin is laminin-521 (LN-521). The second laminin is either laminin-111 (LN-111) or laminin-221 (LN-221). Each laminin can be an intact protein or a protein fragment, although in preferred embodiments the laminins are intact proteins.
(56) The stem cells can be plated on the surface of the cell culture substrate to obtain conventional monolayer cultures (i.e. two-dimensional or 2D). In some alternative embodiments, after plating on the laminin-containing cell culture substrate, the stem cells can be suspended and replated to obtain three-dimensional structures (3D). 3D spheroids can be obtained, for example, using suspension methods or by using a microplate platform that permits control of spheroid size. For example, substrates such as poly(hydroxyethyl methyl methacrylate) (poly-HEMA) or agarose can be used to form the 3D spheroids. The agarose, for example, contains micro wells that control the size to which the aggregate can grow. Other 3D cultivation technologies are known in the art. Suspension culture on low adherence plates can generate a heterogeneous population of aggregates with varying sizes, for example 50 μm to 500 μm.
(57) In particular embodiments, it is contemplated that the weight ratio of the laminin-521 to the laminin-111/211 in the substrate is from about 1:4 to about 1:2, including from about 1:4 to about 1:1 (i.e. less laminin-521 than the laminin-111/211). In particular, laminin-521 and laminin-111 activate α6β1 integrins, which in turn leads to activation of the PI3K/Akt pathway. This increases the pluripotency, self-renewal, and/or proliferation of the differentiated hepatocytes. Many different molecules can activate the PI3K/Akt pathway, though with different efficiencies. For example, TGF beta 1 and bFGF activate this pathway. The use of laminin-521 or laminin-111 allows the quantity of such molecules to be reduced in the cell culture medium. The use of laminin-521 and laminin-511 also allows for single-cell suspension passaging without the addition of cell-detrimental rho-kinase (ROCK) inhibitor to increase cell survival after single-cell enzymatic dissociation.
(58) In some embodiments, the cell culture substrate may also comprise a cadherin. Cadherins are a class of type-1 transmembrane proteins that play important roles in cell adhesion, ensuring that cells within tissues are bound together. They are dependent on calcium (Ca.sup.2+) ions to function. Cadherins are also known as desmogleins and desmocollins. Structurally, cadherins contain extracellular Ca.sup.2+-binding domains. In particular embodiments, the cadherin used in the cell culture substrate is epithelial cadherin or e-cadherin. The weight ratio of the two laminins to the cadherin may be from about 5:1 to about 15:1, or from about 5:1 to about 10:1.
(59) The cell culture substrate is used in combination with multiple cell culture mediums to obtain the desired hepatocytes. Four different cell culture mediums are used, which are described below and referred to herein as mTeSR1, endoderm differentiation medium, hepatoblast differentiation medium, and hepatocyte maturation medium.
(60) The mTeSR1 medium is prepared as described in (Ludwig, T. E., Bergendahl, V., Levenstein, M. E., Yu, J., Probasco M. D. and Thomsom, J. A. (2006); Feeder-independent culture of human embryonic stem cells; Nat Methods 8, 637-646) with several exceptions. First, recombinant human FGF basic (R@DSystems) is used instead of zbFGF. Secondly, Insulin-Transferrin-Selenium Supplement (Invitrogen) added in already made medium was used as a source of the elements instead of the method described in the article. This is commercially available from Stem Cell Technologies (catalog no. 05857).
(61) The endoderm differentiation medium includes RMPI 1640 (Life Technologies catalog no. 11875-093) and 1×B27. B27 supplement without vitamin A can be obtained from Life Technologies (catalog no. 12587-010). Activin A (Peprotech, catalog no. 120-14E) is present in the endoderm differentiation medium in an amount of about 50 ng/mL to about 150 ng/mL, including about 100 ng/mL. Wnt3a (R&D, catalog no. 1324-WN/CF) is present in the endoderm differentiation medium in an amount of about 20 ng/mL to about 80 ng/mL, including about 50 ng/mL.
(62) The hepatoblast differentiation medium is made of 77.5 vol % KO-DMEM (Life Technologies catalog no. 10829-018), 20 vol % Serum Replacement (Life Technologies catalog no. 10828-028), 0.5 vol % Glutamax (Life Technologies catalog no. 35050-038) 1 vol % non-essential amino acids (Life Technologies catalog no. 11140-035), 0.1 mM beta-mercaptoethanol (Life Technologies catalog no. 31350-010), and 1 vol % dimethyl sulfoxide (Life Technologies catalog no. d5879).
(63) The hepatocyte maturation medium made of HepatoZYME™ medium (Life Technologies catalog no. 17705-021), containing 1% Glutamax (Life Technologies catalog no. 35050-038). Hepatocyte growth factor (Peprotech, catalog no. 100-39) is present in the hepatocyte maturation medium in an amount of about 5 ng/mL to about 20 ng/mL, including about 10 ng/mL Oncostatin m (Peprotech, catalog no. 300-10) is also present in the hepatocyte maturation medium, in an amount of about 10 ng/mL to about 30 ng/mL, including about 20 ng/mL. Finally, hydrocortisone is present in the hepatocyte maturation medium at a concentration of about 5 micromolar (μM) to about 20 μM, including about 10 μM.
(64) Returning to
(65) Next, the endoderm differentiation medium is removed, and the hepatoblast differentiation medium is applied to the plated stem cells. The cells are cultured in the hepatoblast differentiation medium for a period of about 108 hours to about 132 hours, including about 120 hours (i.e. five days). The medium may be periodically changed, for example every 48 hours.
(66) Next, the hepatoblast differentiation medium is removed, and the hepatoblast maturation medium is applied to the plated stem cells (2D or 3D). The cells are cultured in the hepatoblast maturation medium for a period of at least 144 hours (i.e. six days). The medium may be periodically changed, for example every 24 hours. This results in a total time period of about 14 days of differentiation and maturation of the stem cells, which differentiate into hepatocytes.
(67) Alternatively, the stem cells are cultured according to the Avior procedure. The Avior procedure uses an endoderm differentiation medium, a hepatic specification medium, a hepatic differentiation medium, and a hepatic maturation medium. The following table identifies all of the ingredients used in each medium in the Avior procedure:
(68) TABLE-US-00001 Medium Ingredient cat no. Source Volume Final Conc. Endoderm RPMI 1640 11875-093 Life 500 mL differentiation Technologies B27 12587-010 Life 10 mL 0.5% Technologies Penicillin-Streptomycin 03-031-1C Biological 5 mL 1% Industries Activin A 338-AC R&D 1 μL/mL 100 ng/ml Wnt3a 5036-WN- R&D 5 μL/mL 50 ng/ml 010 Hepatocyte growth 100-39 Peprotech 0.5 μL/mL 10 ng/mL factor hepatic KO DMEM 10829-018 Life 400 mL specification Technologies KO-SR 10828-028 Life 100 mL 20% Technologies L-Alanyl-L-Glutamin 030221B Biological 2.5 mL 1% (Glutamax) Industries Non Essential Amino 01-340-1B Biological 5 mL 1% Acids (NEAA) Industries Dimethyl sulfoxide D4540 Life 5 mL 1% Technologies beta mecaptoethanol M6250 Life 3.33 mL 0.33 mM Technologies Penicillin-Streptomycin 03-031-1C Biological 5 mL 1% Industries hepatic Iscove's Modified 01-058-1A Biological differentiation Dulbecco's Media Industries (IMDM) Penicillin-Streptomycin 03-031-1C Biological 5 mL 1% Industries Insulin-Transferrin- I3146 Sigma 0.5 mL Selenium Dexmethasone D4902 Sigma 0.5 μL/mL 0.5 μM oncostatin M 300-10 Peprotech 1 μL/mL 20 ng/mL basic fibroblast growth 2 μL/mL 4 ng/mL factor hepatic RPMI-1640 (powder) R6504 Sigma maturation sodum bicarbonate S5761 Sigma Insulin-Transferrin- I2771 Sigma 5 mL 0.10% Selenium + 3 Lithocholic acid L6250 Sigma 1 μL/mL 10 μM Vitamin K (MK-4) V9378 Sigma 1 μL/mL 10 μM Hepatocyte growth 100-39 Peprotech 1 μL/mL 10 ng/mL factor Penicillin-Streptomycin 03-031-1C Biological 5 mL 1% Industries Dexmethasone D4902 Sigma 0.5 μL/mL 0.5 μM
(69) In the Avior procedure, the pluripotent stem cells are cultured in a humidified incubator at 37° C. and 5% CO.sub.2 until the cells reach 50% confluence. Again, the stem cells can have a two-dimensional (2D) or three-dimensional (3D) structure prior to differentiation. Differentiation is initiated by exposing the stem cells to the endoderm differentiation medium for 72 hours, replacing with fresh media every 24 hours. After 72 hours, the cells are exposed to the hepatic specification medium for 4 days, replacing with fresh media every 24 hours. Next, the cells are exposed to the hepatic differentiation medium for 5 days, replacing with fresh media every 24 hours. Finally, the cells are exposed to the hepatic maturation medium for 4 days, replacing with fresh media every 24 hours, for a total of 16 days.
(70) As another alternative, the stem cells are cultured according to the Cameron procedure. The Cameron procedure uses an endoderm differentiation medium, a hepatoblast differentiation medium, and a hepatocyte maturation medium that is very similar to the three mediums described above. The following table identifies all of the ingredients used in each medium in the Cameron procedure:
(71) TABLE-US-00002 Medium Ingredient cat no. Source Volume Final Conc. endoderm RPMI 1640 11875-093 Life 500 mL differentiation Technologies B27 12587-010 Life 10 mL 0.5% Technologies Penicillin-Streptomycin 15140-122 Life 5 mL 1% Technologies Activin A 120-14E Peprotech 1 μL/mL 100 ng/ml Wnt3a 1324- R&D 5 μL/mL 50 ng/ml WN/CF hepatoblast KO DMEM 10829-018 Life 400 mL differentiation Technologies KO-SR 10828-028 Life 100 mL 20% Technologies GlutaMAX-I 35050-038 Life 2.5 mL 1% Technologies Minimal essential 11140-035 Life 5 mL 1% medium Non-Essential Technologies Amino Acids Dimethyl sulfoxide D5879 Life 5 mL 1% Technologies beta mercaptoethanol 31350-010 Life 1 mL 0.1 mM Technologies hepatic HepatoZYME-SFM 17705-021 Life 500 mL maturation Technolgies GlutaMAX-I 35050-038 Life 2.5 mL 1% Technologies hydrocortisone- 21 H4881-1G Sigma 5 mL 10 μM hemisuccinate sodium salt Hepatocyte growth 100-39 Peprotech 1 μL/mL 20 ng/mL factor oncostatin M 300-10 Peprotech 1 μL/mL 10 ng/mL Penicillin-Streptomycin 15140-122 Life 5 mL 1% Technologies
(72) In the Cameron procedure, the pluripotent stem cells are cultured in a humidified incubator at 37° C. and 5% CO.sub.2 until the cells reach 20 to 30% confluence. Again, the stem cells can have a two-dimensional (2D) or three-dimensional (3D) structure prior to differentiation. Differentiation is initiated by replacing culture medium with the endoderm differentiation medium. The media is replaced with fresh media every 24 hours for a period of 72 hours. After 72 hours, the media is replaced with the hepatocyte differentiation medium for 5 days, replacing every 48 hours. After 5 days, the media is replaced with the hepatocyte maturation medium, changing every 48 hours until day 20. The cells gradually exhibit morphological changes from a spiky and triangular shape to a characteristic liver morphology displaying a polygonal appearance.
(73) After about 14 days, the identity of the cells (i.e. that they have differentiated into hepatocytes) can be verified by expression of markers including CYP3A4, CYP1A2, Oct4, Nanog, albumin, alpha fetoprotein (AFP), FOXA2, HNF4A, SOX17, CK19, and CYP2D6. The hepatocytes are then ready for use in desired applications.
(74) The cell culture systems formed by the cell culture substrate and the various cell culture mediums work extremely well for producing hepatocytes from stem cells in a completely defined environment and xeno-free conditions without feeders or any inhibitors of apoptosis. It is noted that hepatocytes produced by the Cameron procedure are generally more stable than those produced by the Avior procedure, in that they possess Cytochrome P450 1A2 and 3A activity for a longer time period (10 days vs 1-2 days). It is contemplated that the cell culture system will be completely defined and xeno-free. The system (i.e. both the substrate and any cell culture mediums) should also be devoid of any differentiation inhibitors, feeder cells, or differentiation inductors, or apoptosis inhibitors. Examples of feeder cells include mouse fibroblasts or human foreskin fibroblasts. Examples of differentiation inductors include Noggin or keratinocyte growth factor.
(75) The following examples are for purposes of further illustrating the present disclosure. The examples are merely illustrative and are not intended to limit devices made in accordance with the disclosure to the materials, conditions, or process parameters set forth therein.
EXAMPLES
Example 1
(76) Cell Culture
(77) H9 human embryonic stem cells (hESCs) were cultured and maintained in a humidified 37° C., 5% CO.sub.2 incubator. Three different substrates were then prepared in 96-well plates. The first substrate was pre-coated with Matrigel® (MG), and served as a control. The second substrate was coated with 5 micrograms per square centimeter (μg/cm.sup.2) of laminin-521 (LN-521). The third substrate was coated with 5 μg/cm.sup.2 of a blend of laminin-521 and laminin-111 at a 1:3 weight ratio (Biolamina, Sweden) (abbreviated here as LN-111).
(78) Differentiation was initiated at 40% confluence, by replacing serum-free medium mTESR1 (Stem Cell Technologies) with endoderm differentiation medium-RPMI 1640 containing 1×B27 (Life Technologies), 100 ng/mL Activin A (PeproTech) and 50 ng/mL Wnt3a (R&D). The medium was changed every 24 hours, for 72 hours. On day 4, endoderm differentiation medium was replaced with hepatoblast differentiation medium, and this was renewed every second day for a further five days. The medium consisted of KO-DMEM (Life Technologies), Serum Replacement (Life Technologies), 0.5% Glutamax (Life Technologies), 1% non-essential amino acids (Life Technologies), 0.2% β-mercaptoethanol (Life Technologies) and 1% dimethyl sulfoxide (Sigma) for 5 days. At Day 9, differentiating cells were cultured in hepatocyte maturation medium HepatoZYME (Life Technologies) containing 1% Glutamax (Life Technologies), supplemented with 10 ng/mL hepatocyte growth factor (Peprotech) and 20 ng/mL oncostatin m (Peprotech).
(79) Cryoplateable human hepatocytes were plated and maintained according to the instructions of vendor Life Technologies. Briefly, cryoplateable hepatocytes were resuscitated in thawing medium (Life Technologies, catalog no. CM3000) and plated onto the pre-coated 96 well plates. Cells-attached to all matrices efficiently and were maintained in an incubator set at 37 degrees Celsius and CO.sub.2 levels set to 5%. At 24 hours post-plating, the medium was changed to an incubation medium (catalog no. CM4000).
(80)
(81) Methods
(82) Total RNA was isolated from cells using Trizol reagent. RNA quantification and quality was assessed using a Nanodrop system. The Life Technologies Superscript III reverse transcription kit was employed to prepare the cDNA. Quantitative PCR was performed with Taqman Fast Advance Mastermix and the appropriate primer pair and analysed using a Roche LightCycler 480 Real-Time PCR System. Gene expression was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and expressed as relative expression over the control sample (hESC on Day 0 of differentiation). Quantitative PCRs were performed in triplicate. Data analysis was performed using Roche LightCycler 480 Software (version 1.5). Levels of significance were measured by the statistical function student t-test, wherein significant values are those with a p-value less than 0.05.
(83) Immunocytochemistry analysis was subsequently performed on hESC-derived hepatocytes. Cell cultures were fixed in 100% ice-cold methanol at −20 degrees Celsius for 30 minutes, and adjacent cells were pre-washed twice with PBS buffer at room temperature. Cell monolayers were blocked with 0.1% PBS-Tween solution containing 10% bovine serum albumin for 1 hour. Subsequently, the monolayers were incubated with primary antibodies diluted in PBS-0.1% Tween/1% BSA at 4 degrees Celsius overnight. After 24 hours, the primary antibodies were removed and the fixed monolayers were washed three times with PBS-0.1% Tween/1% BSA. Cells were incubated with appropriate secondary antibodies diluted in PBS-0.1% Tween/1% BSA for one hour at room temperature and washed with three times with PBS. Cultures were then mounted with PermaFluor™ Aqueous Mounting Medium and counterstained with NucBlue Hoescht 33342. The cells were imaged with the Zeiss Axio Observer Z1 microscope with LD PlanNeoFluar objective lenses, and a Zeiss AxioCamMR3 camera was used for image acquisition. The images were processed through Zeiss Axiovision SE 64 Rel 4.8 and analyzed using Zeiss Axiovision version 4.9.1.0. The percentage of positive cells and standard deviation was estimated from at least five random fields of view.
(84) Before Differentiation
(85)
(86) Cells on all three matrices adhered, proliferated, and differentiated into hepatocyte like cells (HLCs). After 24 hours post-replating, ESCs displayed appropriate characteristic cell morphology, including appropriate expression levels of stem cell associated markers OCT4 and Nanog, with subtle differences on each substrate, as seen in Rows A, B, and C of
(87) TABLE-US-00003 Expression Levels Substrate OCT4 Nanog MG 88.3% ± 4.8 86.7% ± 5.0 LN-521 93.2% ± 5.9 88.7% ± 5.4 LN-511 93.8% ± 2.4 90.4% ± 3.5
(88) Differentiation Analysis
(89) Twenty four hours post-replating, differentiation was initiated using a serum free procedure. Cell extracts were collected during differentiation and mRNA assessed on days 0, 3, 9, and 18. Of note, all differentiation procedures delivered cell populations that transited from pluripotency, through definitive endoderm, to hepatoblast like cells and subsequently hepatocytes as demonstrated by quantitative PCR. It should be remembered that the “LN-511” label refers to a substrate containing a blend of laminin-521 and laminin-111 at a 1:3 weight ratio.
(90)
(91) Hepatoblast Specification
(92) Next, the efficiency of the differentiation process was measured.
(93) TABLE-US-00004 Substrate FOXA2 SOX17 AFP HNF4A CK19 MG 82.8% ± 2.1 74.8% ± 8.3 90.8% ± 1.1 88.5% ± 2.5 96.8% ± 2.0 LN-521 80.4% ± 3.5 92.6% ± 1.8 98.3% ± 0.9 86.4% ± 2.3 98.5% ± 1.0 LN-111 88.1% ± 2.3 87.2% ± 6.9 95.3% ± 2.0 85.9% ± 1.8 97.2% ± 1.5
(94) FOXA2 was expressed on all substrates at day 3. The majority of cells on the MG, LN-521 and LN-111 substrates. SOX17 staining was more varied across the three substrates; it was lowest on MG and highest on LN-521. As cell differentiation progressed and hepatic fate was specified, cells began expressing high levels of hepatoblast markers. AFP, HNF4a, and CK19 were expressed in the majority of cells on all three substrates. Hepatoblast specification on all three substrates appeared equivalent and highly efficient, and the initial differences in hESC morphology observed on the three substrates did not appear to affect the kinetics or the efficiency of cellular differentiation using this procedure. However, an approximately 2-fold increase in cell size was observed in hepatocytes differentiated on the LN-521 and LN-511 substrates (see the CK19 photomicrographs). As shown, hepatoblast specification on all three matrices appeared equivalent and highly efficient. Any initial differences in hESC morphology observed on the three matrices did not appear to affect the kinetics, efficiency or cellular differentiation.
(95) Hepatocyte Maturation
(96) Post-hepatoblast specification, cell cultures were differentiated toward hepatocytes. Hepatocyte specification was assessed by immunostaining for albumin (ALB), E-cadherin (E CAD), cellular proliferation marker (Ki67), cytochrome p450 2D6 (CYP2D6), and cytochrome p450 3A4 (CYP3A4).
(97)
(98) TABLE-US-00005 Substrate Albumin E CAD Ki67 MG 91.6% ± 0.7 76.5% ± 0.7 29.8% ± 3.7 LN-521 89.5% ± 8.7 67.4% ± 4.4 17.4% ± 6.2 LN-511 91.3% ± 4.0 73.7% ± 3.7 15.9% ± 6.6
(99) Similar patterns of protein production between the matrigel and laminin populations were observed. Albumin staining was detected in cells on all three substrates, with the highest expression on the MG substrate and the lowest on the LN-521 substrate. E-cadherin (E CAD) is important in regulating hepatocyte cell to cell contact and involved in cell spatial regulation. Expression was highest on the MG and LN-111 substrates. However, on the LN-521 substrate foci with brighter staining were observed. While immunostaining studies showed equivalence between the populations, differences in cell division were observed on the different substrates with more cells undergoing proliferation on the MG substrate compared to the LN-521 and LN-111 substrates.
(100) Hepatocyte Function
(101) Given that cell organisation and cell division are important factors in hepatocyte function, hepatocyte metabolic capacity in vitro was studied. Stem cell derived hepatocytes were first examined for cytochrome P450 expression using well characterised antisera. CYP3A and CYP1A2 activity were measured from days 16-26 using pGlo technology. CYP activity was expressed as relative light units (RLU) per milliliter of media per milligram of protein. Levels of significance were measured by student t-test.
(102)
(103) TABLE-US-00006 Substrate CYP2D6 CYP3A MG 84.4% ± 2.1 95.4% ± 2.6 LN-521 85.7% ± 5.7 91.3% ± 3.7 LN-111 82.5% ± 5.0 90.6% ± 2.9
(104) All of the cells expressed high levels of each marker on each substrate. While protein expression appeared equivalent, stem cell hepatocyte CYP function varied dramatically, as seen in the two bar graphs. On the LN-111 substrate, CYP1A2 activity increased over time and was significantly higher than the MG substrate over all time points. On laminin-521, CYP1A2 activity was elevated and at all time was significantly greater than it was on the control. On day 26, cells on both laminin substrates demonstrated significant more CYP1A2 function than primary human hepatocytes in culture (indicated by dotted line). CYP3A function was increased by up to 25-fold on the LN-111 substrate. Cells on both laminin substrates exhibited significantly increased metabolic function relative to cells on the MG control substrate and primary hepatocytes.
(105) To determine whether these large changes in metabolic capacity correlated to increased protein production, the production of albumin and alpha fetoprotein (AFP) from hESC-derived and cryoplatable hepatocytes was quantified using commercially available enzyme-linked immunosorbent assay (ELISA) kits. The different media were collected at denoted time points during hESC differentiation, days 20-26. Primary hepatocyte media was harvested at 24 hours post plating onto commercially available medium or laminin coated surfaces. Samples were run in triplicate and measured on a FLUOStar Omega multi-mode microplate reader. Protein production was expressed as ng or μg of protein per milliliter of media, per milligram of protein. The results are shown in
(106) Functional Organization
(107)
(108) The top row (A) of photomicrographs shows phase contrast images. Stem-cell derived hepatocytes cultured on the LN-521 and LN-111 substrates displayed a more primary hepatocyte-like appearance, often bi-nucleate with very pronounced nuclei. The phase contrast images also indicated hepatocytes were arranged in lobule-like structures within the culture dish, reminiscent of regenerating liver.
(109) The middle row (B) shows co-immunostaining for MRP1 and HNF4a. Around these lobule structures, positive staining for MRP-1, an important basal membrane marker, was detected. Only hepatocytes differentiated on the LN-521 and LN-111 substrates exhibited networks of organised hepatocytes in vitro. This was in stark contrast to cells on the MG substrate, which displayed more individual and punctate staining.
(110) To determine whether these cells were capable of biliary efflux, cells were treated with 5(6)-carboxy-2′,7′-dichlorofluorescein diacetate (CDFDA), which was metabolised to fluorescent CDF and effluxed by multidrug resistance associated protein 2 (MRP2). hESC-derived hepatocytes were incubated with 2 μM of 5(6)-carboxy-2′,7′dichlorofluorescein diacetate (CDFDA) for 30 minutes. Cultures were then washed with ice-cold PBS containing calcium and magnesium. Cells were either collected for imaging or retained for quantification of efflux. For fluorescent quantification, hepatic maturation was replaced and cells incubated at 37 degrees Celsius for 30 minutes. The efflux of CDFDA from cells into media was measured by fluorescence spectroscopy at 485/585 nm using a FLUOStar Omega multi-mode microplate reader.
(111) The results are shown in the bottom row (C) of photomicrographs. Notably, cell organisation was paralleled by more active biliary efflux in cells differentiated on the LN-521 and LN-111 substrates versus the MG substrate.
(112) Genome-Wide Analysis
(113) The results discussed above demonstrated an improvement in the stem cell differentiation to hepatocytes on laminins. To understand which gene regulatory networks underpinned this, an extensive and unbiased bioinformatics analysis was performed. For this purpose, ESCs were differentiated on the MG, LN-521, and LN-511 substrates. It should be remembered that the “LN-511” label refers to a substrate containing a blend of laminin-521 and laminin-111 at a 1:3 weight ratio. The standard differentiation protocol was applied and whole-genome expression profiles of three independent experiments were analyzed. Data were compared to a previous study (Godoy et al., J. Hepatol., 2015 May 25, pii: S0168-8278(15)00340-2, doi: 10.1016/j.jhep.2015.05.013) which used freshly-isolated primary human hepatocytes (FH), ESCs and Matrigel®-differentiated hepatocyte-like cells (HLC, D17 and D21). These data were then compared to the stem-cell derived hepatocytes of the MG, LN-521, and LN-511 substrates (D24, L521 and L111 respectively).
(114)
(115)
(116)
(117) TABLE-US-00007 Mean Expression Sample Type Level Cluster 2 = 528 gene (I) hESC −1.75 MG (day 17) −0.5 MG (day 21) −0.25 MG (day 24) −0.25 LN-521 (day 24) 0 LN-111 (day 24) 0 Cluster 11 =108 gene (I) hESC −7 MG (day 17) −2 MG (day 21) −2 MG (day 24) −1.75 LN-521 (day 24) −1 LN-111 (day 24) −1 Cluster 3 = 73 gene (II) hESC −7.5 MG (day 17) −7 MG (day 21) −7 MG (day 24) −7 LN-521 (day 24) −7 LN-111 (day 24) −6.5 Cluster 14 = 352 gene (II) hESC −3 MG (day 17) −2.5 MG (day 21) −2.5 MG (day 24) −2.5 LN-521 (day 24) −2.5 LN-111 (day 24) −2.5 Cluster 17 = 204 gene (II) hESC −5.5 MG (day 17) −4.5 MG (day 21) −4 MG (day 24) −4 LN-521 (day 24) −4 LN-111 (day 24) −4 Cluster 8 = 747 gene (II) hESC −2 MG (day 17) −0.75 MG (day 21) −0.5 MG (day 24) −0.75 LN-521 (day 24) −0.5 LN-111 (day 24) −0.5 Cluster 5 = 580 gene (III) hESC 2.5 MG (day 17) 1.5 MG (day 21) 1.25 MG (day 24) 1.1 LN-521 (day 24) 0.9 LN-111 (day 24) 0.9 Cluster 10 = 336 gene (III) hESC 3.5 MG (day 17) 2.5 MG (day 21) 2.25 MG (day 24) 2.25 LN-521 (day 24) 2 LN-111 (day 24) 2 Cluster 6 = 217 gene (IV) hESC 4.1 MG (day 17) 4 MG (day 21) 4 MG (day 24) 4 LN-521 (day 24) 3.75 LN-111 (day 24) 3.75 Cluster 1 = 191 gene (V) hESC 0.25 MG (day 17) 2.25 MG (day 21) 2.5 MG (day 24) 3 LN-521 (day 24) 3 LN-111 (day 24) 2.5 Cluster 4 = 509 gene (V) hESC −0.5 MG (day 17) 0.5 MG (day 21) 0.75 MG (day 24) 1 LN-521 (day 24) 1.25 LN-111 (day 24) 1.25 Cluster 12 = 73 gene (V) hESC 4.5 MG (day 17) 6 MG (day 21) 6 MG (day 24) 6 LN-521 (day 24) 6 LN-111 (day 24) 6
(118) Clustering of genes with similar expression patterns in HLCs generated three superclusters representing the motifs “mature liver functions,” “proliferation,” and “extracellular matrix (ECM)/migration.” The KEGG and GO motifs are overrepresented in each gene cluster. Representative genes for each cluster and motif are also indicated. Genes listed in italics of Cluster V were expressed in lower levels in HLCs on the LN-111 substrate compared to the control MG substrate. Significant differences in mean gene expression levels were observed between the control MG substrate and the LN-521 and LN-111 substrates in clusters 5, 10 and 6, which correspond to the supercluster “proliferation.” In all three proliferation-associated clusters, the laminin substrates led to a significantly stronger suppression than the MG substrate (clusters III and IV;
(119)
(120) Discussion
(121) Three different substrates were tested, one the control Matrigel® substrate, and the other two containing laminins. While similar numbers of stem cell derived hepatocytes were produced on the three substrates, overt differences were observed in their cell assembly, organisation and function. By mimicking key elements of the liver cell niche, using two laminin isoforms, hepatocyte differentiation was dramatically improved, significantly enhancing cell organisation and function. Notably, CYP1A2 and CYP3A function were equivalent or superior to primary human hepatocytes when stem cell derived hepatocytes were cultured on the laminins, and they remained stable for several days in culture. Enhanced hepatocyte organisation on both laminins was evidenced by MRP1 staining, and resulted in improved canalicular excretion of CDFDA, suggesting a mature feature of stem cell derived hepatocytes in vitro
(122) These observations were consistent with better hepatocyte organisation and CYP P450 activities in cell populations differentiated on the laminin-containing substrates. Given the different roles that laminin plays in liver biology, studies were extended to current gold standard sources, primary hepatocytes from male and female donors. Notably, as was observed for hESC hepatocytes, laminin coated surfaces better supported CYP p450 activity, but did not significantly improve albumin secretion.
(123) Since analysis of some selected liver markers suggested an improvement of liver differentiation when using laminin substrates compared to Matrigel®, genome-wide expression analysis was performed. A first goal was to answer whether different substrates/matrices caused dramatic or only minor changes in overall gene expression. Previous studies have shown that the type of matrix can cause major phenotypic alteration such as differences in cell polarity and sensitivity to apoptosis. Considering the number of differentially expressed genes in the present study (556 between the Matrigel® and the LN-521 substrates, and 664 between the Matrigel and the LN-111 blended substrates, FDR adjusted) the difference may be considered as major. It can be concluded that the laminin-containing substrates imparted three specific features compared to the Matrigel® control substrate. First, expression of stemness genes was more effectively suppressed, with a four-fold reduction in stem cell markers LIN28A and c-kit on laminins. Second, the blend of laminin-521 and laminin-111 more efficiently suppressed proliferation-associated gene expression. Third, induction of unwanted colon-associated and fibroblast-associate gene expression, which is an inherent side effect of the currently used hepatocyte differentiation protocols, was ameliorated by laminin-111. Therefore, genome-wide analysis clearly identified improvement of HLCs differentiated on laminin-containing substrates. Importantly, individual genes where the presence of laminin-111 improved the hepatocyte differentiation can be identified. For example, C3, haptoglobin, plasminogen and the transcription factor FXR increased at least 2-fold on the laminin-111-containing substrate compared to the Matrigel® substrate.
(124) The present results showed the supportive properties of recombinant laminins in the context of stem-cell derived hepatocyte differentiation and metabolic function. hESC-derived hepatocytes displayed improved morphology, organisation, stability and cell function on human laminins, which was comparable to male and female primary hepatocytes.
Example 2
(125) Stem-cell derived hepatocytes were produced from human embryonic stem cells on three different substrates. The first substrate was pure laminin-521 (LN-521). The second substrate was a mix of laminin-521 and laminin-221 in a weight ratio of 1:3 (221 (1:3)), i.e. three times more laminin-221. The third substrate was a mix of laminin-221 and laminin-521 in a weight ratio of 1:1 (221 (1:1)). At day 18, cells were fixed and stained for multidrug resistance protein 1 (MPR1).
(126)
Example 3
(127) Stem-cell derived hepatocytes were produced from human embryonic stem cells on three different substrates. The first substrate was pure laminin-521 (LN-521). The second substrate was a mix of laminin-521 and laminin-221 in a weight ratio of 1:3 (221 (1:3)). The third substrate was a mix of laminin-221 and laminin-521 in a weight ratio of 1:1 (221 (1:1)). The Cameron procedure and the Avior procedure were compared to each other.
(128)
(129) Cells plated on the 221 (1:3) substrate performed better than those plated on the LN-521 or 221 (1:1) substrates. Notably, when adult hepatocyte function (CYP1A2) was measured, stem cell derived hepatocytes via the Cameron procedure performed better than those delivered by the Avior procedure. When fetal and adult liver function (CYP3A) was measured, the Avior procedure demonstrated better performance. LCA and MK4 elicited major toxic effects on stem cell derived hepatocytes resulting in cell death at day 18 using the Avior procedure. Typically stem cell derived hepatocytes display function and viability for 27 days in the differentiation process, indicating the Cameron procedure yields more stable hepatocyte and adult like populations in vitro when compared to the Avior procedure.
Example 4
(130) MAN12 cells, a GMP grade cell line, were plated on three different substrates. The first substrate was Matrigel® (MG), and served as a control. The second substrate was coated with 5 micrograms per square centimeter (μg/cm.sup.2) of laminin-521 (LN-521). The third substrate was coated with 5 μg/cm.sup.2 of a blend of laminin-521 and laminin-111 at a 1:3 weight ratio (Biolamina, Sweden) (abbreviated here as LN-111). The cells were then differentiated according to the Cameron protocol.
(131)
(132)
(133) TABLE-US-00008 Substrate ALB CYP3A MG 87.5% ± 4.8 87.5% ± 4.8 LN-521 83.3% ± 8.5 81.5% ± 8.6 LN-511 88.8% ± 6.0 80.2% ± 3.1
Example 5
(134) MAN11 cells, another GMP grade cell line, were plated on three different substrates. The first substrate was Matrigel® (MG), and served as a control. The second substrate was coated with 5 micrograms per square centimeter (μg/cm.sup.2) of laminin-521 (LN-521). The third substrate was coated with 5 μg/cm.sup.2 of a blend of laminin-521 and laminin-111 at a 1:3 weight ratio (Biolamina, Sweden) (abbreviated here as LN-111). The cells were then differentiated according to the Cameron protocol.
(135)
(136) TABLE-US-00009 Substrate ALB CYP3A MG 89.2% ± 7.3 85.5% ± 8.1 LN-521 89.2% ± 6.0 90.8% ± 9.9 LN-511 89.7% ± 5.5 89.5% ± 5.5
(137)
(138) Looking at both Example 4 and Example 5, the MAN11 and MAN12 cells differentiated efficiently on all three substrates, with the majority of cells (>80%) expressing albumin and CYP3A, as detected by immunostaining. The same level of cellular organisation was also demonstrated across the three substrates, though morphologically the cells were more defined on the laminin-containing substrates and displayed distinct hexagonal morphology. Furthermore, HLCs on the LN-521 and the LN-111 substrates displayed networks of MRP1 staining; indicating these cell populations were more polarised. Of note, H9 derived hepatocytes displayed a closer metabolic profile to primary hepatocytes than did MAN11 and MAN12 derived hepatocytes. However, both the LN-512 and the LN-111 substrates improved metabolic activity of MAN12 derived hepatocytes and significantly reduced foetal protein secretion in MAN11 derived hepatocytes, demonstrating significant progress.
Example 6
(139) Differentiation of Pluripotent Stem Cells Towards Hepatocytes.
(140) Cultured hESCs on pure laminin-521 coated wells were dissociated into single cells and resuspended into ROCK inhibitor supplemented mTeSR1. To make random size spheroids, 2 ml of 1×10.sup.6 cell suspension was transferred into poly-hydroxyethyl methyl methacrylate (poly-HEMA)-coated 6-well plates and incubated under static conditions overnight (
(141) Gene Expression Analysis
(142) To analyse gene expression, spheroids were collected at the denoted time points and mRNA were extracted. Both procedures delivered cell populations from H9 (research grade line) and Man12 (GMP grade line) that transited from pluripotency, through definitive endoderm, to hepatoblast-like cells and subsequently hepatocytes as demonstrated by quantitative PCR. FOXA2 expression was detected from days 3-18 (
(143) Maturation of Human Embryonic Stem Cell Derived Hepatospheres
(144) In order to assess maturation of 3D hepatospheres, expression of hepatic markers such as hepatic nuclear factor 4A (HNF4A), and E-cadherin (Ecad) were stained for at day 18 (
(145) Human Embryonic Stem Cell Derived Hepatocyte Metabolic Function
(146) In order to assess metabolic competence of human stem cell derived hepatopheres, cytochrome P450 expression was examined using antisera. CYP3A and CY2D6 expression were detected throughout the 3D hepatospheres (
(147) Human Embryonic Stem Cell Derived Hepatocyte Function In Vivo
(148) In order to assess the competence of two-dimensional (2D) and three-dimensional (3D) stem cell derived hepatocytes to support murine liver function, the partial hepatectomy model of reduced liver function was employed. 2 million 2D or 3D hepatocytes were transplanted intra portally or intra peritoneally respectively. For the 2D cells, 48 hours after transplant a 30% partial hepatectomy was carried out. For the 3D cells, cells were transplanted into the peritoneum at the same time as performing the hepatectomy. 7 days post partial hepatectomy mouse body weight was recorded. Body weight was significantly increased in both transplant groups when compared to the vehicle only control. The control was about 91% initial body weight, while the 2D group was about 95% initial body weight, and the 3D group was about 100% initial body weight.
(149) We been developed to a 3D system to derive functional hepatocyte-like cells with stable phenotype. Both protocols resulted in efficient production of spheroids from hPSC cultured and maintained on laminin 521, however, control over the size of formed spheroids was challenging using suspension methodology. In contrast, the size of spheroids can be controlled using microplate platform with small variation in spheroid size.
(150) 3D hepatospheres showed more stable phenotype and prolonged metabolic functionality up to day 60 of differentiation Furthermore, hepatocyte-like cells derived under 3D conditions displayed highly polarized structures evident by expression of e-cadherin and ZO-1. Notably, a lower number of proliferating cells was observed in small hepatospheres at day 18, while a higher number was detected in larger spheroids, indicating the importance of size in regulation of cell behaviour. Importantly, 3D hepatospheres demonstrated suitable function in vitro and also supported mammalian liver function in vivo.
(151) The present disclosure has been described with reference to exemplary embodiments. Obviously, modifications and alterations will occur to others upon reading and understanding the preceding detailed description. It is intended that the present disclosure be construed as including all such modifications and alterations insofar that they come within the scope of the appended claims or the equivalents thereof.